\BOOKMARK [0][-]{section*.4}{Glossary}{}% 1
\BOOKMARK [0][-]{section*.6}{Acronyms}{}% 2
\BOOKMARK [0][-]{chapter.1}{Introduction and Literature Review}{}% 3
\BOOKMARK [1][-]{section.1.1}{Cancer Research in the Post-Genomic Era}{chapter.1}% 4
\BOOKMARK [2][-]{subsection.1.1.1}{Cancer is a Global Health Issue}{section.1.1}% 5
\BOOKMARK [3][-]{subsubsection.1.1.1.1}{The Genetics and Molecular Biology of Cancers}{subsection.1.1.1}% 6
\BOOKMARK [2][-]{subsection.1.1.2}{The Genomics Revolution in Cancer Research}{section.1.1}% 7
\BOOKMARK [3][-]{subsubsection.1.1.2.1}{High-Throughput Technologies}{subsection.1.1.2}% 8
\BOOKMARK [3][-]{subsubsection.1.1.2.2}{Bioinformatics and Genomic Data}{subsection.1.1.2}% 9
\BOOKMARK [2][-]{subsection.1.1.3}{Genomics Projects}{section.1.1}% 10
\BOOKMARK [3][-]{subsubsection.1.1.3.1}{The Cancer Genome Project}{subsection.1.1.3}% 11
\BOOKMARK [3][-]{subsubsection.1.1.3.2}{The Cancer Genome Atlas Project}{subsection.1.1.3}% 12
\BOOKMARK [2][-]{subsection.1.1.4}{Genomic Cancer Medicine}{section.1.1}% 13
\BOOKMARK [3][-]{subsubsection.1.1.4.1}{Cancer Genes and Driver Mutations}{subsection.1.1.4}% 14
\BOOKMARK [3][-]{subsubsection.1.1.4.2}{Precision Cancer Medicine}{subsection.1.1.4}% 15
\BOOKMARK [3][-]{subsubsection.1.1.4.3}{Molecular Diagnostics and Pan-Cancer Medicine}{subsection.1.1.4}% 16
\BOOKMARK [3][-]{subsubsection.1.1.4.4}{Targeted Therapeutics and Pharmacogenomics}{subsection.1.1.4}% 17
\BOOKMARK [2][-]{subsection.1.1.5}{Systems and Network Biology}{section.1.1}% 18
\BOOKMARK [1][-]{section.1.2}{Synthetic Lethal Cancer Medicine}{chapter.1}% 19
\BOOKMARK [2][-]{subsection.1.2.1}{Synthetic Lethal Genetic Interactions}{section.1.2}% 20
\BOOKMARK [2][-]{subsection.1.2.2}{Synthetic Lethal Concepts in Genetics}{section.1.2}% 21
\BOOKMARK [2][-]{subsection.1.2.3}{Synthetic Lethality in Model Systems}{section.1.2}% 22
\BOOKMARK [3][-]{subsubsection.1.2.3.1}{Synthetic Lethal Pathways and Networks}{subsection.1.2.3}% 23
\BOOKMARK [3][-]{subsubsection.1.2.3.2}{Evolution of Synthetic Lethality}{subsection.1.2.3}% 24
\BOOKMARK [2][-]{subsection.1.2.4}{Synthetic Lethality in Cancer}{section.1.2}% 25
\BOOKMARK [2][-]{subsection.1.2.5}{Clinical Impact of Synthetic Lethality in Cancer}{section.1.2}% 26
\BOOKMARK [2][-]{subsection.1.2.6}{High-throughput Screening for Synthetic Lethality}{section.1.2}% 27
\BOOKMARK [3][-]{subsubsection.1.2.6.1}{Synthetic Lethal Screens}{subsection.1.2.6}% 28
\BOOKMARK [2][-]{subsection.1.2.7}{Computational Prediction of Synthetic Lethality}{section.1.2}% 29
\BOOKMARK [3][-]{subsubsection.1.2.7.1}{Bioinformatics Approaches to Genetic Interactions}{subsection.1.2.7}% 30
\BOOKMARK [3][-]{subsubsection.1.2.7.2}{Comparative Genomics}{subsection.1.2.7}% 31
\BOOKMARK [3][-]{subsubsection.1.2.7.3}{Analysis and Modelling of Protein Data}{subsection.1.2.7}% 32
\BOOKMARK [3][-]{subsubsection.1.2.7.4}{Differential Gene Expression}{subsection.1.2.7}% 33
\BOOKMARK [3][-]{subsubsection.1.2.7.5}{Data Mining and Machine Learning}{subsection.1.2.7}% 34
\BOOKMARK [3][-]{subsubsection.1.2.7.6}{Mutual Exclusivity and Bimodality}{subsection.1.2.7}% 35
\BOOKMARK [3][-]{subsubsection.1.2.7.7}{Rationale for Further Development}{subsection.1.2.7}% 36
\BOOKMARK [1][-]{section.1.3}{E-cadherin as a Synthetic Lethal Target}{chapter.1}% 37
\BOOKMARK [2][-]{subsection.1.3.1}{The CDH1 gene and its Biological Functions}{section.1.3}% 38
\BOOKMARK [2][-]{subsection.1.3.2}{Hereditary Diffuse Gastric \(and Lobular Breast\) Cancer}{section.1.3}% 39
\BOOKMARK [2][-]{subsection.1.3.3}{Cell Line Models of CDH1 Null Mutations}{section.1.3}% 40
\BOOKMARK [1][-]{section.1.4}{Summary and Research Direction of Thesis}{chapter.1}% 41
\BOOKMARK [2][-]{subsection.1.4.1}{Thesis Aims}{section.1.4}% 42
\BOOKMARK [0][-]{chapter.2}{Methods and Resources}{}% 43
\BOOKMARK [1][-]{section.2.1}{Bioinformatics Resources for Genomics Research}{chapter.2}% 44
\BOOKMARK [2][-]{subsection.2.1.1}{Public Data and Software Packages}{section.2.1}% 45
\BOOKMARK [3][-]{subsubsection.2.1.1.1}{Cancer Genome Atlas Data}{subsection.2.1.1}% 46
\BOOKMARK [3][-]{subsubsection.2.1.1.2}{Reactome and Annotation Data}{subsection.2.1.1}% 47
\BOOKMARK [1][-]{section.2.2}{Data Handling}{chapter.2}% 48
\BOOKMARK [2][-]{subsection.2.2.1}{Normalisation}{section.2.2}% 49
\BOOKMARK [2][-]{subsection.2.2.2}{Sample Triage}{section.2.2}% 50
\BOOKMARK [2][-]{subsection.2.2.3}{Metagenes and the Singular Value Decomposition}{section.2.2}% 51
\BOOKMARK [2][-]{subsection.2.2.4}{Candidate Triage and Integration with Screen Data}{section.2.2}% 52
\BOOKMARK [1][-]{section.2.3}{Techniques}{chapter.2}% 53
\BOOKMARK [2][-]{subsection.2.3.1}{Statistical Procedures and Tests}{section.2.3}% 54
\BOOKMARK [2][-]{subsection.2.3.2}{Gene Set Over-representation Analysis}{section.2.3}% 55
\BOOKMARK [2][-]{subsection.2.3.3}{Clustering}{section.2.3}% 56
\BOOKMARK [2][-]{subsection.2.3.4}{Heatmap}{section.2.3}% 57
\BOOKMARK [2][-]{subsection.2.3.5}{Modelling and Simulations}{section.2.3}% 58
\BOOKMARK [3][-]{subsubsection.2.3.5.1}{Receiver Operating Characteristic Curves}{subsection.2.3.5}% 59
\BOOKMARK [2][-]{subsection.2.3.6}{Resampling Analysis}{section.2.3}% 60
\BOOKMARK [1][-]{section.2.4}{Pathway Structure Methods}{chapter.2}% 61
\BOOKMARK [2][-]{subsection.2.4.1}{Network and Graph Analysis}{section.2.4}% 62
\BOOKMARK [2][-]{subsection.2.4.2}{Sourcing Graph Structure Data}{section.2.4}% 63
\BOOKMARK [2][-]{subsection.2.4.3}{Constructing Pathway Subgraphs}{section.2.4}% 64
\BOOKMARK [2][-]{subsection.2.4.4}{Network Analysis Metrics}{section.2.4}% 65
\BOOKMARK [1][-]{section.2.5}{Implementation}{chapter.2}% 66
\BOOKMARK [2][-]{subsection.2.5.1}{Computational Resources and Linux Utilities}{section.2.5}% 67
\BOOKMARK [2][-]{subsection.2.5.2}{R Language and Packages}{section.2.5}% 68
\BOOKMARK [2][-]{subsection.2.5.3}{High Performance and Parallel Computing}{section.2.5}% 69
\BOOKMARK [0][-]{chapter.3}{Methods Developed During Thesis}{}% 70
\BOOKMARK [1][-]{section.3.1}{A Synthetic Lethal Detection Methodology}{chapter.3}% 71
\BOOKMARK [1][-]{section.3.2}{Synthetic Lethal Simulation and Modelling}{chapter.3}% 72
\BOOKMARK [2][-]{subsection.3.2.1}{A Model of Synthetic Lethality in Expression Data}{section.3.2}% 73
\BOOKMARK [2][-]{subsection.3.2.2}{Simulation Procedure}{section.3.2}% 74
\BOOKMARK [1][-]{section.3.3}{Detecting Simulated Synthetic Lethal Partners}{chapter.3}% 75
\BOOKMARK [2][-]{subsection.3.3.1}{Binomial Simulation of Synthetic Lethality}{section.3.3}% 76
\BOOKMARK [2][-]{subsection.3.3.2}{Multivariate Normal Simulation of Synthetic Lethality}{section.3.3}% 77
\BOOKMARK [3][-]{subsubsection.3.3.2.1}{Multivariate Normal Simulation with Correlated Genes}{subsection.3.3.2}% 78
\BOOKMARK [3][-]{subsubsection.3.3.2.2}{Specificity with Query-Correlated Pathways}{subsection.3.3.2}% 79
\BOOKMARK [1][-]{section.3.4}{Graph Structure Methods}{chapter.3}% 80
\BOOKMARK [2][-]{subsection.3.4.1}{Upstream and Downstream Gene Detection}{section.3.4}% 81
\BOOKMARK [3][-]{subsubsection.3.4.1.1}{Permutation Analysis for Statistical Significance}{subsection.3.4.1}% 82
\BOOKMARK [2][-]{subsection.3.4.2}{Simulating Gene Expression from Graph Structures}{section.3.4}% 83
\BOOKMARK [1][-]{section.3.5}{Customised Functions and Packages Developed}{chapter.3}% 84
\BOOKMARK [2][-]{subsection.3.5.1}{Synthetic Lethal Interaction Prediction Tool}{section.3.5}% 85
\BOOKMARK [2][-]{subsection.3.5.2}{Data Visualisation}{section.3.5}% 86
\BOOKMARK [2][-]{subsection.3.5.3}{Extensions to the iGraph Package}{section.3.5}% 87
\BOOKMARK [3][-]{subsubsection.3.5.3.1}{Sampling Simulated Data from Graph Structures}{subsection.3.5.3}% 88
\BOOKMARK [3][-]{subsubsection.3.5.3.2}{Plotting Directed Graph Structures}{subsection.3.5.3}% 89
\BOOKMARK [3][-]{subsubsection.3.5.3.3}{Computing Information Centrality}{subsection.3.5.3}% 90
\BOOKMARK [3][-]{subsubsection.3.5.3.4}{Testing Pathway Structure with Permutation Testing}{subsection.3.5.3}% 91
\BOOKMARK [3][-]{subsubsection.3.5.3.5}{Metapackage to Install iGraph Functions}{subsection.3.5.3}% 92
\BOOKMARK [0][-]{chapter.4}{Synthetic Lethal Analysis of Gene Expression Data}{}% 93
\BOOKMARK [1][-]{section.4.1}{Synthetic Lethal Genes in Breast Cancer}{chapter.4}% 94
\BOOKMARK [2][-]{subsection.4.1.1}{Synthetic Lethal Pathways in Breast Cancer}{section.4.1}% 95
\BOOKMARK [2][-]{subsection.4.1.2}{Expression Profiles of Synthetic Lethal Partners}{section.4.1}% 96
\BOOKMARK [3][-]{subsubsection.4.1.2.1}{Subgroup Pathway Analysis}{subsection.4.1.2}% 97
\BOOKMARK [1][-]{section.4.2}{Comparing Synthetic Lethal Gene Candidates}{chapter.4}% 98
\BOOKMARK [2][-]{subsection.4.2.1}{Primary siRNA Screen Candidates}{section.4.2}% 99
\BOOKMARK [2][-]{subsection.4.2.2}{Comparison with Correlation}{section.4.2}% 100
\BOOKMARK [2][-]{subsection.4.2.3}{Comparison with Primary Screen Viability}{section.4.2}% 101
\BOOKMARK [2][-]{subsection.4.2.4}{Comparison with Secondary siRNA Screen Validation}{section.4.2}% 102
\BOOKMARK [2][-]{subsection.4.2.5}{Comparison to Primary Screen at Pathway Level}{section.4.2}% 103
\BOOKMARK [3][-]{subsubsection.4.2.5.1}{Resampling Genes for Pathway Enrichment}{subsection.4.2.5}% 104
\BOOKMARK [2][-]{subsection.4.2.6}{Integrating Synthetic Lethal Pathways and Screens}{section.4.2}% 105
\BOOKMARK [1][-]{section.4.3}{Synthetic Lethal Pathway Metagenes}{chapter.4}% 106
\BOOKMARK [1][-]{section.4.4}{Replication in Stomach Cancer}{chapter.4}% 107
\BOOKMARK [1][-]{section.4.5}{Discussion}{chapter.4}% 108
\BOOKMARK [2][-]{subsection.4.5.1}{Strengths of the SLIPT Methodology}{section.4.5}% 109
\BOOKMARK [2][-]{subsection.4.5.2}{Synthetic Lethal Pathways for E-cadherin}{section.4.5}% 110
\BOOKMARK [2][-]{subsection.4.5.3}{Replication and Validation}{section.4.5}% 111
\BOOKMARK [3][-]{subsubsection.4.5.3.1}{Integration with siRNA Screening}{subsection.4.5.3}% 112
\BOOKMARK [3][-]{subsubsection.4.5.3.2}{Replication across Tissues}{subsection.4.5.3}% 113
\BOOKMARK [1][-]{section.4.6}{Summary}{chapter.4}% 114
\BOOKMARK [0][-]{chapter.5}{Synthetic Lethal Pathway Structure}{}% 115
\BOOKMARK [1][-]{section.5.1}{Synthetic Lethal Genes in Reactome Pathways}{chapter.5}% 116
\BOOKMARK [2][-]{subsection.5.1.1}{The PI3K/AKT Pathway}{section.5.1}% 117
\BOOKMARK [2][-]{subsection.5.1.2}{The Extracellular Matrix}{section.5.1}% 118
\BOOKMARK [2][-]{subsection.5.1.3}{G Protein Coupled Receptors}{section.5.1}% 119
\BOOKMARK [2][-]{subsection.5.1.4}{Gene Regulation and Translation}{section.5.1}% 120
\BOOKMARK [1][-]{section.5.2}{Network Analysis of Synthetic Lethal Genes}{chapter.5}% 121
\BOOKMARK [2][-]{subsection.5.2.1}{Gene Connectivity and Vertex Degree}{section.5.2}% 122
\BOOKMARK [2][-]{subsection.5.2.2}{Gene Importance and Centrality}{section.5.2}% 123
\BOOKMARK [3][-]{subsubsection.5.2.2.1}{Information Centrality}{subsection.5.2.2}% 124
\BOOKMARK [3][-]{subsubsection.5.2.2.2}{PageRank Centrality}{subsection.5.2.2}% 125
\BOOKMARK [1][-]{section.5.3}{Relationships between Synthetic Lethal Genes}{chapter.5}% 126
\BOOKMARK [2][-]{subsection.5.3.1}{Detecting Upstream or Downstream Synthetic Lethality}{section.5.3}% 127
\BOOKMARK [2][-]{subsection.5.3.2}{Resampling for Synthetic Lethal Pathway Structure}{section.5.3}% 128
\BOOKMARK [1][-]{section.5.4}{Discussion}{chapter.5}% 129
\BOOKMARK [1][-]{section.5.5}{Summary}{chapter.5}% 130
\BOOKMARK [0][-]{chapter.6}{Simulation and Modelling of Synthetic Lethal Pathways}{}% 131
\BOOKMARK [1][-]{section.6.1}{Synthetic Lethal Detection Methods}{chapter.6}% 132
\BOOKMARK [2][-]{subsection.6.1.1}{Performance of SLIPT and 2 across Quantiles}{section.6.1}% 133
\BOOKMARK [3][-]{subsubsection.6.1.1.1}{Correlated Query Genes affects Specificity}{subsection.6.1.1}% 134
\BOOKMARK [2][-]{subsection.6.1.2}{Alternative Synthetic Lethal Detection Strategies}{section.6.1}% 135
\BOOKMARK [3][-]{subsubsection.6.1.2.1}{Correlation for Synthetic Lethal Detection}{subsection.6.1.2}% 136
\BOOKMARK [3][-]{subsubsection.6.1.2.2}{Testing for Bimodality with BiSEp}{subsection.6.1.2}% 137
\BOOKMARK [1][-]{section.6.2}{Simulations with Graph Structures}{chapter.6}% 138
\BOOKMARK [2][-]{subsection.6.2.1}{Performance over Graph Structures}{section.6.2}% 139
\BOOKMARK [3][-]{subsubsection.6.2.1.1}{Simple Graph Structures}{subsection.6.2.1}% 140
\BOOKMARK [3][-]{subsubsection.6.2.1.2}{Constructed Graph Structures}{subsection.6.2.1}% 141
\BOOKMARK [2][-]{subsection.6.2.2}{Performance with Inhibitions}{section.6.2}% 142
\BOOKMARK [2][-]{subsection.6.2.3}{Synthetic Lethality across Graph Structures}{section.6.2}% 143
\BOOKMARK [2][-]{subsection.6.2.4}{Performance within a Large Simulated Datasets}{section.6.2}% 144
\BOOKMARK [1][-]{section.6.3}{Simulations in More Complex Graph Structures}{chapter.6}% 145
\BOOKMARK [2][-]{subsection.6.3.1}{Simulations over Pathway-based Graphs}{section.6.3}% 146
\BOOKMARK [2][-]{subsection.6.3.2}{Pathway Structures in a Large Simulated Datasets}{section.6.3}% 147
\BOOKMARK [1][-]{section.6.4}{Discussion}{chapter.6}% 148
\BOOKMARK [2][-]{subsection.6.4.1}{Simulation Procedure}{section.6.4}% 149
\BOOKMARK [2][-]{subsection.6.4.2}{Comparing Methods with Simulated Data}{section.6.4}% 150
\BOOKMARK [2][-]{subsection.6.4.3}{Design and Performance of SLIPT}{section.6.4}% 151
\BOOKMARK [2][-]{subsection.6.4.4}{Simulations from Graph Structures}{section.6.4}% 152
\BOOKMARK [1][-]{section.6.5}{Summary}{chapter.6}% 153
\BOOKMARK [0][-]{chapter.7}{Discussion}{}% 154
\BOOKMARK [1][-]{section.7.1}{Synthetic Lethality and CDH1 Biology}{chapter.7}% 155
\BOOKMARK [2][-]{subsection.7.1.1}{Established Functions of CDH1}{section.7.1}% 156
\BOOKMARK [2][-]{subsection.7.1.2}{The Molecular Role of CDH1 in Cancer}{section.7.1}% 157
\BOOKMARK [1][-]{section.7.2}{Significance}{chapter.7}% 158
\BOOKMARK [2][-]{subsection.7.2.1}{Synthetic Lethality in the Genomic Era}{section.7.2}% 159
\BOOKMARK [2][-]{subsection.7.2.2}{Clinical Interventions based on Synthetic Lethality}{section.7.2}% 160
\BOOKMARK [1][-]{section.7.3}{Future Directions}{chapter.7}% 161
\BOOKMARK [1][-]{section.7.4}{Conclusions}{chapter.7}% 162
\BOOKMARK [0][-]{section.7.4}{Bibliography}{}% 163
\BOOKMARK [0][-]{appendix.A}{Sample Quality}{}% 164
\BOOKMARK [1][-]{section.A.1}{Sample Correlation}{appendix.A}% 165
\BOOKMARK [1][-]{section.A.2}{Replicate Samples in TCGA Breast Cancer Data}{appendix.A}% 166
\BOOKMARK [0][-]{appendix.B}{Software Used for Thesis}{}% 167
\BOOKMARK [0][-]{appendix.C}{Mutation Analysis in Breast Cancer}{}% 168
\BOOKMARK [1][-]{section.C.1}{Synthetic Lethal Genes and Pathways}{appendix.C}% 169
\BOOKMARK [1][-]{section.C.2}{Synthetic Lethal Expression Profiles}{appendix.C}% 170
\BOOKMARK [1][-]{section.C.3}{Comparison to Primary Screen}{appendix.C}% 171
\BOOKMARK [2][-]{subsection.C.3.1}{Resampling Analysis}{section.C.3}% 172
\BOOKMARK [1][-]{section.C.4}{Compare SLIPT genes}{appendix.C}% 173
\BOOKMARK [0][-]{appendix.D}{Metagene Analysis}{}% 174
\BOOKMARK [1][-]{section.D.1}{Pathway Signature Expression}{appendix.D}% 175
\BOOKMARK [1][-]{section.D.2}{Synthetic Lethal Reactome Metagenes}{appendix.D}% 176
\BOOKMARK [0][-]{appendix.E}{Intrinsic Subtyping}{}% 177
\BOOKMARK [0][-]{appendix.F}{Stomach Expression Analysis}{}% 178
\BOOKMARK [1][-]{section.F.1}{Synthetic Lethal Genes and Pathways}{appendix.F}% 179
\BOOKMARK [1][-]{section.F.2}{Comparison to Primary Screen}{appendix.F}% 180
\BOOKMARK [2][-]{subsection.F.2.1}{Resampling Analysis}{section.F.2}% 181
\BOOKMARK [1][-]{section.F.3}{Metagene Analysis}{appendix.F}% 182
\BOOKMARK [0][-]{appendix.G}{Synthetic Lethal Genes in Pathways}{}% 183
\BOOKMARK [0][-]{appendix.H}{Network Analysis for Mutation SLIPT}{}% 184
\BOOKMARK [0][-]{appendix.I}{Pathway Structure for Mutation SLIPT}{}% 185
\BOOKMARK [0][-]{appendix.J}{Performance of SLIPT and 2}{}% 186
\BOOKMARK [1][-]{section.J.1}{Correlated Query Genes affects Specificity}{appendix.J}% 187
\BOOKMARK [0][-]{appendix.K}{Simulations on Graph Structures}{}% 188
\BOOKMARK [1][-]{subsection.K.0.1}{Simulations from Inhibiting Graph Structures}{appendix.K}% 189
\BOOKMARK [1][-]{section.K.1}{Simulation across Graph Structures}{appendix.K}% 190
\BOOKMARK [1][-]{section.K.2}{Simulations from Complex Graph Structures}{appendix.K}% 191
\BOOKMARK [2][-]{subsection.K.2.1}{Simulations from Complex Inhibiting Graphs}{section.K.2}% 192
\BOOKMARK [1][-]{section.K.3}{Simulations from Pathway Graph Structures}{appendix.K}% 193
